Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Reference: Trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
Study: Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02) HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast cancer Trastuzumab-deruxtecan (n=406) vs. SOC (n=202) Efficacy: mPFS: 17.8 vs 6.9 mos, p
New Indication: Tucatinib with trastuzumab for colorectal cancer (MOUNTAİNEER)
Study: Phase II, open-label, multicenter study Pretreated, HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer Tucatinib + Trastuzumab q21 (n=117) Efficacy: ORR: 38% [28-49] DoR: 12.4 mos [8.5-20.5] Safety: Any
New Protocol – A Phase 2 Study of Pemigatinib in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement 8 (FIGHT-203)
Study: Phase 2, open label, multicenter trial Myeloid/Lymphoid Neoplasms 28 patients ≥1 prior therapy Pemigatinib 13.5 mg daily (2 wks; 1 wk off) No prior therapy Pemigatinib 13.5
New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study: Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles Efficacy:
New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)
Study: Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1) zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1)
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study: Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281) Efficacy:
New Indication: Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer
Study: Randomized, two-group, open- label, phase 3 trial HER2- low, unresectable or metastatic breast cancer One or two previous lines of chemotherapy Trastuzumab deruxtecan (N:373) or the physician’s choice of
New Protocol: FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of HER 2–Positive Resectable Esophagogastric Adenocarcinoma
Study: Multicenter, randomized phase II/III trial HER 2–positive, >= clinical tumor 2 or clinical nodal–positive resectable EGA Four pre and postoperative cycles of either FLOT alone (N:41) or combined with
New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer
Study: Multicenter, nonrandomized phase II study HER2-mutated, advanced NSCLC with ≥ one previous line including platinums Pertuzumab+trastuzumab+docetaxel (n=45) Efficacy: ORR: 29%, SD: 58% mPFS: 6.8 mos, mOS: 17.6 mos 5
New Indication: Trastuzumab deruxtecan for her2+ NSCLC
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight Efficacy: ORR: 55% (95% CI, 44 to